AAV

PerkinElmer has launched ready-to-use adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of serious diseases.   The validated and fully automatable assays are built on PerkinElmer’s AlphaLISA technology which requires no separation and are optimised, no-wash AAV detection assays. The new offering provides researchers expanded options to measure […]

Complement Therapeutics’ lead asset CTx001, an AAV-based gene therapy for the treatment of geographic atrophy (GA), has been awarded an Innovation Passport by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).  CTx001 was awarded the Innovation Passport based on three criteria: that the condition addressed is seriously debilitating with a significant patient need; an […]

The Cell and Gene Therapy Catapult (CGT Catapult) has partnered with the UK Dementia Research Institute (UK DRI) to help advance the development of adeno-associated virus (AAV) based gene therapies for dementia.  Through the collaboration, the CGT Catapult will work with UK academic centres and the UK DRI to identify new AAV-based gene therapies that […]

 Mirus Bio outlines when to use transfection reagents, viral transduction or electroporation   No single delivery method is ideal for all situations, but researchers may routinely employ a suboptimal approach for the sake of familiarity or to avoid any start-up costs associated with new methods.   The uses of nucleic acid delivery have expanded from recombinant […]

NanoTemper Technologies has launched a number of updates to its portfolio of instruments to help researchers working in drug discovery and adeno-associated virus (AAV) therapies.  NanoTemper Technologies has launched its Spectral Shift technology to remove the roadblocks experienced by scientists dealing with really complex molecular interactions often seen in challenging drugs and drug targets like […]

PerkinElmer’s SIRION Biotech business and the Centre for Genomic Regulation (CRG) have agreed to jointly develop new generation adeno-associated virus (AAV) vectors for Type 1 and Type 2 diabetes gene therapy in the pancreas.  The collaboration  The collaboration combines SIRION’s AAV technology platform and expertise in viral vector development and production with CRG’s deep knowledge […]